Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer
Related Experiment Video
Updated: Jun 15, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Mackenzie Cook1, Xiao-Min Yu, Herbert Chen
1Section of Endocrine Surgery, Department of Surgery, University of Wisconsin Madison, Wisconsin.
Abstract:
The Notch pathway plays an important role in the normal development of neuroendocrine cells, including the calcitonin producing C-cells of the thyroid. This effect has been elucidated to be mediated through modulation of Achaete-Scute Complex Like 1 (ASCL1), a transcription factor associated with poor prognosis in neuroendocrine cancer. Medullary thyroid cancer (MTC) is one of the neuroendocrine cancers derived from the thyroid C-cells. The Notch pathway has been shown to be inactive in MTC which may lead to altered expression of ASCL1. Artificial induction of Notch signaling in MTC cells can suppress ASCL1 expression, the cell growth as well as hormone secreting potential. Pharmacological activation of the Notch pathway also successfully suppresses the tumor growth in an animal model, which sheds light on the targeted therapy of Notch as a potential treatment for intractable MTC.
Insights
Activating the Notch pathway in medullary thyroid cancer (MTC) suppresses Achaete-Scute Complex Like 1 (ASCL1) expression and tumor growth. This suggests Notch pathway activation is a promising targeted therapy for MTC.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- The Notch pathway is crucial for neuroendocrine cell development, including thyroid C-cells.
- Achaete-Scute Complex Like 1 (ASCL1), a transcription factor, is linked to poor prognosis in neuroendocrine cancers.
- Medullary thyroid cancer (MTC) originates from thyroid C-cells and typically exhibits inactive Notch signaling.
Purpose of the Study:
- To investigate the role of Notch pathway inactivity in MTC pathogenesis.
- To explore the therapeutic potential of Notch pathway activation in MTC.
Main Methods:
- In vitro studies involving artificial induction of Notch signaling in MTC cells.
- In vivo studies using an animal model of MTC treated with pharmacological Notch pathway activators.
Main Results:
- Artificial Notch signaling induction suppressed ASCL1 expression, cell growth, and hormone secretion in MTC cells.
- Pharmacological activation of the Notch pathway significantly inhibited tumor growth in an MTC animal model.
Conclusions:
- Notch pathway inactivation contributes to MTC development by altering ASCL1 expression.
- Targeted activation of the Notch pathway represents a potential therapeutic strategy for treating MTC.
Related Concept Videos
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Synthesis and Functions of Calcitonin
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
The Thyroid Gland
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...

